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BACKGROUND: To date, there are few reports on gene products contributing to colon cancer progression.
METHODS: We used a gene trap comprised of an enhanced retroviral mutagen (ERM) cassette that includes a tetracycline-responsive
promoter upstream of a haemagglutinin (HA) tag and a splice donor site. Integration of the ERM within an endogenous gene yields a
tetracycline-regulated HA-tagged transcript. We transduced RKO colon cancer cells expressing a tetracycline trans-activator-off with
the ERM-encoding retrovirus and screened for enhanced migration.
RESULTS: One clone showed fivefold enhanced migration with tetracycline withdrawal. Rapid amplification of cDNA ends identified the
trapped gene as the chloride channel 4 (CLCN4) exchanger. Stable expression of a CLCN4 cDNA enhanced motility, whereas cells
knocked down or null for this transcript showed reduced migration/invasion. CLCN4-overexpressing RKO colon cancer cells were
more resistant than controls to proton load-induced cytotoxicity, consistent with the H
þ-extruding function of this antiporter. Intra-
splenic delivery of RKO-CLCN4 transfectants, but not controls, yielded liver metastases, and transcript levels were higher in colon
cancer metastases to the liver when compared with primary tumours.
CONCLUSIONS: CLCN4 is a novel driver of colon cancer progression.
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Sporadic colorectal cancer, afflicting 145000 persons per year in
the United States (de la Chapelle, 2004), largely reflects aberrantly
activated pathways, leading to unrestrained growth. In the Wnt
pathway, adenomatous polyposis coli truncations stabilise
b-catenin, leading to the trans-activation of target genes causal
for growth (Heyer et al, 1999). Mutation-activated K-Ras (Aktas
et al, 1997) also promotes tumour growth, whereas mutation of the
type II transforming growth factor b (TGF-b) receptor gene (TGF-
b RII) generating a truncated protein is incapable of restraining
growth (Derynck et al, 2001). Mutation inactivation of the p53
tumour suppressor renders damaged cells unable to arrest for
DNA repair, leading to the mutation of key genes crucial to tumour
development (Levine, 1997). Emerging studies also indicate that
the heterogeneity of this disease probably also involves the
contribution of multiple other gene products (Tomlinson et al,
2007; Wood et al, 2007) acting in various combinations to promote
cancer development and progression.
Although the aforementioned observations have provided
invaluable insight into the molecular mechanisms responsible for
colorectal cancer development, there have been relatively few
studies that identify gene products contributing to colon cancer
cell migration, invasion and metastases (Cajot et al, 1997; Guan
et al, 2000; Minard et al, 2005; Samuels et al, 2005). As one
example, Drg-1, identified by differential display, is downregulated
in its expression in metastatic colon cancer and its forced
overexpression reduces in vitro invasion of colon cancer, these
findings leading the authors to propose Drg-1 as a metastatic
suppressor (Guan et al, 2000). Similarly, expression of motility-
related protein (MRP1/CD9) is highly repressed in metastases
compared with primary colorectal tumours, and anti-MRP1/CD9
antibodies abrogate tumour cell migration (Cajot et al, 1997).
Conversely, the PIK3CA gene is mutated in B30% of colorectal
cancers (Samuels et al, 2004) and these alterations generate a
protein that facilitates tumour invasion (Samuels et al, 2005).
Considering the paucity of studies to identify genes regulatory for
colon cancer cell migration/invasion, we undertook an unbiased,
genome-wide approach to discover novel genes stimulatory for
colon cancer cell migration. Towards this end, we used a gene-trap
method (Liu et al, 2000; Lin and Elledge, 2003) (see Figure 1 for
strategy) using a retroviral enhanced retroviral mutagen (ERM)
cassette. The ERM includes a haemagglutinin (HA) tag and a splice
donor site under the control of a tetracycline-responsive promoter.
On retroviral transduction of tetracycline trans-activator-expressing
cells, if the ERM is integrated intra-genically, the endogenous gene
is brought under the control of the tetracycline-responsive
promoter and the spliced ‘gene-trapped’ transcript can be
identified by the HA tag sequence using rapid amplification of
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scDNA ends (30-RACE). Using this gene-trap system, we report herein
the identification of chloride channel 4 (CLCN4)a san o v e lg e n e
product that enhances colon cancer migration and metastases.
MATERIALS AND METHODS
Cell lines
The RKO and HCT 116 colon cancer cell lines were all established
from resected primary colon tumours (Brattain et al, 1981, 1984).
LS174 cells were derived from a colon adenocarcinoma that had
spread to the pericolonic fibroadipose tissue (Kahan et al, 1976).
ClCN4 wild-type and null mouse fibroblasts have been described
elsewhere (Mohammad-Panah et al, 2009).
Design of modified ERM vectors
Enhanced retroviral mutagen vectors are pBabe-puro based. The
ERM cassette, comprising of a tetracycline-responsive promoter,
an HA Tag and an artificial splice donor (AAGGTAAGT), was
cloned into the NheI site at the 30 long terminal repeat sequence.
A set of three ERM vectors were constructed in which the ERM
Tags were in all three possible reading frames: RF1, RF2 and RF3.
All plasmids (RF1, RF2, RF3, PCGP, VSV, tetracycline trans-
activator (tTA)) were propagated in Escherichia coli DH5a cells.
Construction of CLCN4 expression constructs
Full-length CLCN4 cDNA was purchased from the American Type
Culture Collection (ATCC-X77197; cat. no.8427856) and subcloned
into the BlueScript vector. The CLCN4 cDNA sequence was then
subcloned into the multicloning site of pcDNA3.1( ) using EcoRI
and BamHI enzymes to generate the CLCN4 pcDNA 3.1 construct.
A partial cDNA sequence was then generated by PCR to include the
NsiI site located within the CLCN4 sequence and extending to the
30 end of the cDNA. The 30 primer was designed to include an HA
sequence, followed by a stop codon and a BamHI site. The CLCN4
pcDNA 3.1 construct was digested with NsiI and BamHI to
generate a 50 fragment of the cDNA sequence. The 50 and
HA-tagged 30 CLCN4 sequences digested with NsiI and BamHI
were then ligated. To generate truncated CLCN4 cDNA, the CLCN4
pcDNA 3.1 construct was digested with XbaI to delete the 50 coding
sequence (restriction sites are located in the vector multicloning
site and there is a unique site in the cDNA sequence) and
autoligated, thus engineering a cDNA corresponding to the
trapped endogenous gene.
Virus production
293T cells were maintained in Dulbecco’s modified Eagle’s
medium containing 10% (v/v) foetal calf serum (FCS). 293T cells
(9 10
6) were seeded in 10ml of 10% FCS for 12h before
transfection. HEPES-buffered saline solution (pH 7.05; 1ml) was
added to an equal volume of DNA/CaCl2 solution containing 8mg
of transfer vector construct, 6mg of gag/pol packaging plasmid and
4mg of VSVg envelope plasmid, and the resulting solution was
immediately added to the above medium. The cells were then
returned to the 321C incubator (5% CO2) for 8h. Subsequently, the
medium was changed to 10ml of fresh 10% FCS, and 48h later, the
medium was removed, centrifuged at 500 g for 5min and filtered
through a 0.45mm filter. The virus supernatant was stored at
 801C in aliquots for subsequent infection of cancer cells in MOI
(multiplicity of infection) of 1:1.
Cancer cells infection with ERM retrovirus
Colon cancer cells were maintained in McCoy’s 5A medium
supplemented with 10% foetal bovine serum. Cancer cells were
plated in 100mm plates (5 10
5 cells per plate) and infected with
the virus supernatant of the tTA in the presence of 4mg/ml
polybrene. The medium was changed to McCoy’s 5A/10% CS 5h
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Figure 1 Schematic of gene-trapping experimental strategy. LTR, long terminal repeat; SA, splice acceptor; tTA, tetracycline-responsive trans-activator.
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slater. Cells were harvested 48h later and selected in G418. Cancer
cells expressing the tetracycline-responsive promoter trans-
activator (tTA) were infected with ERM virus supernatants as
described above, except for puromycin selection (1mg/ml), and
then expanded for further analysis.
To determine the viral titre, antibiotic selections (G418 for tTA
and puromycin for RF1, 2, 3) were performed as above, except
that, at 48h after infection, the cells were split at a 1:100 ratio into
selection medium, fed every 3 days and the colonies were counted
10 days later. In determining the G418-resistance titre, the number
of colonies was divided by four to account for two cell doublings.
Transformed colonies in selected areas were enumerated 10 days
after infection.
Migration Assays
Unless specified otherwise, cells (5 10
4) were suspended in 0.1ml
of 0.1% albumin-containing culture medium and dispensed into
the upper chambers of Transwells (8mm pore size), with 0.6ml of
10% FBS-containing medium in the lower chamber. After 6–8h,
cells on the upper surface were removed with a cotton swab, and
cells migrating to the lower membrane surface were either
detached with trypsin or stained with haematoxylin/eosin or
Hema-Diff.
Identification of target genes
To identify trapped genes, total RNA was extracted from expanded
clones using RNeasy Mini Kits (Qiagen, Valencia, CA, USA).
Reverse transcription (RT) was performed with a primer RT-1
(50-GCAAATACGACTCACTATAGGGATCCNNNN(GC)ACG-30)c o n -
taining the random sequence NNNN and using the Superscript III
kit (Invitrogen, Carlsbad, CA, USA). The 50 end of the primer
corresponds to the T7 primer sequence. The cDNA was then PCR
amplified using an ERM-specific primer (50-GACACCGGGACC
GATCCAG-30) and the T7 primer (T7-2, 50-GCAAATACGACT
CACTATAGGGATC-30) using AccuTaq DNA polymerase (Invitro-
gen). The PCR products were gel purified, directly sequenced and
nucleotide sequences were searched against the human non-
redundant Genebank and expressed sequence tag (EST) databases
using the Basic Local Alignment Search Tool (Blast, http://
blast.ncbi.nlm.nih.gov/Blast.cgi).
Reverse transcription-Polymerase Chain Reaction
The RNA was isolated using the RNAeasy Mini Kit (Qiagen)
according to the manufacturer’s instructions. Reverse transcrip-
tion was performed from 2mg of RNA using SuperscriptII
(Invitrogen). The cDNA was then PCR amplified using Taq DNA
polymerase (PGC Scientific, Garner, NC, USA). Primers used for
CLCN4 were as follows: forward 50-GGACGAGTTTACTCACCGCA-30
(in exon 11) and reverse 50-GGTCCTGGTTTGCCATCTGG-30 (in
exon 13). The Tm values were 58 and 611C, respectively, and 35
cycles of PCR were used.
Quantitative PCR
The RNA was extracted using Trizol as per the manufacturer’s
instructions (Invitrogen) and reverse transcribed at 371C for 2h
using 2mg RNA as input. Quantitation was performed using a 7500
real-time PCR system (Applied Biosystems, Foster City, CA, USA)
and the Taqman gene expression assay for CLCN4 (Applied
Biosystems assay; ID-HS001565411_m1; cat. no. 70771B2) with
primers spanning the exon 4–5 boundary. GAPDH transcript
levels were used as an internal control (Applied Biosystems cat. no.
4333764F). Results were calculated using the comparative thresh-
old cycle (Ct) method of relative quantitation, as described by the
manufacturer.
Cell invasion assays
Cell invasion assays were carried out using Matrigel-precoated
Transwell chambers (8mm pore size). Unless indicated otherwise,
cells (5 10
5) suspended in 0.125ml of serum-free medium
containing 0.5% BSA were added to each upper well and cells in
0.75ml of medium containing 10 or 20% FBS were added to the
corresponding lower well. After 16–22h, non-invasive cells were
removed from the upper aspect of the membrane by scrubbing
with a cotton swab and cells on the lower aspect were either
recovered with trypsin and enumerated or fixed and stained using
Hema-Diff, as instructed by the manufacturer (StatLab, McKinney,
TX, USA).
Scratch/wound migration assay
Near confluent cells were scratch wounded with a sterile pipette
tip, the monolayer changed to fresh medium containing 1% FBS
and images captured at 0 and 24h. Migration distances were
determined using a superimposed digital 5mm scale bar.
siRNA knockdowns
The following CLCN-4-targeting and non-targeting siRNAs from
Ambion (Austin, TX, USA) were used: no. 1 (cat no. 16708A SiRNA
ID no. 7181; sense GGUGGCAAUUAUUUUCAGAtt; antisense
UCUGAAAAUAAUUGCCACCtt) no. 2 (cat no. 16708A SiRNA ID
no. 104393; sense GGCUGAUGUUUGUAACUUAtt; antisense
UAAGUUACAAACAUCAGCCtt); no. 3 (cat no. 16708A SiRNA
ID no. 146048; sense GGACGAGUUUACUCACCGCtt; antisense
GCGGUGAGUAAACUCGUCCtt). The non-targeting control was
the silencer negative control SiRNA (cat no. 4635).
DNA transfection
Lipofectamine 2000 was used for delivery of plasmid DNA and
siRNA into the colon cancer cells as per the manufacturer’s
instructions (Invitrogen).
Transduction of colon cancer cells with an shRNA
targeting CLCN4
LS174 cells were transduced with CLCN4 lentiviral particles
encoding an anti-CLCN4 shRNA (SH-006152-03-10) or a non-
targeting shRNA (S-005000-01) (Lentigen, Gaithersburg, MD,
USA) using 10mgml
 1 polybrene at 10 MOI. Cells were puromycin
(10mgml
 1) selected and fluorescence activated cell sorted for high
EGFP expression. The recovered cells were expanded.
Statistical analysis
Data were expressed as the mean±standard error (s.e.). Unless
indicated otherwise, an unpaired t-test was used to determine
whether differences were statistically different using GraphPad
Prism software (v 5.02, La Jolla, CA, USA). A P-value of o0.05 was
considered to be statistically significant.
Experimental metastases assay
Cells (10
6) were inoculated into the spleen of nude mice as
described previously (Jessup et al, 1989) and, after 6 weeks, livers
were examined macroscopically for metastatic disease.
Western blotting
Cells were lysed with a buffer (15mM NaCl, 10mM Tris (pH 7.4),
1% TritonX-100, 0.5% Igepal (Sigma I3021, St Louis, MO, USA),
1m M EDTA, 1mM EGTA (pH 7.4), 200mM PMSF and protease
inhibitor cocktail (Roche 11836153001, Indianapolis, IN, USA)).
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transferred for 2h at 100V to a PDF membrane. Protein detection
was performed by sequential hybridisation with a 1:500 dilution of
an anti-HA rabbit antibody (Invitrogen cat no. 715500) and 1:2500
dilution of a goat anti-rabbit-HRP-conjugated antibody.
RESULTS
Gene trapping of CLCN4
We first infected RKO colon cancer cells with a retrovirus
encoding a tTA expression plasmid and isolated tetracycline-
responsive clones using a tTA-responsive luciferase reporter. One
clone, showing a fourfold induction in response to tetracycline
removal (data not shown), was used for subsequent gene trapping.
We infected these cells with the ERM retrovirus to generate a
library of gene-trapped cells, and transwell motility assays were
performed thrice sequentially to select for cells with enhanced
migration. Accordingly, 97 independent clones showing augmen-
ted migration were isolated and, of these, 13 showed increased
migration in the absence, but not in the presence, of tetracycline.
One clone (RKO-ERM no. 28) manifested a robust (Bsixfold,
Po0.05) increase in migration on tetracycline removal
(Figure 2A), whereas the RKO cells expressing only tTA showed
no modulation on tetracycline withdrawal. We isolated total RNA
from RKO-ERM no. 28 cells and performed 30 RACE with the ERM
tag sequence to identify the trapped endogenous gene. A homology
search revealed the trapped gene to be CLCN4. Reverse transcrip-
tion-PCR showed that tetracycline removal caused a robust
induction of a transcript using primers corresponding to the
CLCN4 message for the RKO-ERM no. 28 clone but not with the
tTA-expressing RKO cells (Figure 2B). The 30 RACE indicated that
the CLCN4 gene was trapped at exon 7. Analysis of the predicted
protein sequence by Ensembl (www.ensembl.org) and the SMART
protein prediction algorithm (http://smart.embl-heidelberg.de)
indicated four Prints domains (http://www.bioinf.man.ac.uk/
dbbrowser/PRINTS/index.php) constituting the CLCN4 encoded
by exons 7–9, as well as the two cystathionine b-synthase motifs
encoded by exons 8 and 9. In addition, four transmembrane-
spanning segments encoded by exons 7 and 8 were present in the
gene-trapped product.
We pursued CLCN4 for several reasons. First, the gene is
encoded at Xp22.3, a chromosomal region that shows gain in 16%
of colon cancer patients (http://130.60.44.174/progenetix/). Second,
CLCN4 is an H
þ/Cl
  exchanger (in which the movement of Cl
  in
one direction is coupled to the movement of protons in the
opposite direction) and chloride fluxes have been shown to
modulate cell migration (Ransom et al, 2001). Third, persistent
metabolism of glucose to lactate by tumour cells (adaptative
response to hypoxia) (Gatenby and Gillies, 2004) requires a
mechanism for proton extrusion to prevent acidosis-induced
cytotoxicity.
Validation of the gene-trapped CLCN4 as a regulator of
colon cancer cell migration
It remained a formal possibility that the tetracycline-responsive
promoter was modulating a gene(s) neighbouring CLCN4 that was
causal for the altered migration. Further, as the endogenous
CLCN4 gene was trapped at exon 7 (determined by 30 RACE), the
expressed truncated protein (Supplementary Data 1), while
retaining much of the chloride channel structure, might invoke a
biological effect unrelated to its physiological role. Thus, to
validate the gene-trapped CLCN4 as an inducer of tumour cell
migration, the following experiments were performed. First, we
used a siRNA strategy to determine whether silencing of the
endogenous gene (induced by tetracycline withdrawal) in RKO-
ERM no. 28 cells would counter cell migration. Of three
independent siRNAs tested, two (siRNA no. 1 and no. 2) were
effective in countering CLCN4 expression in RKO-ERM no. 28 cells
(Figure 3A) induced by tetracycline withdrawal. Moreover,
transient transfection of CLCN4-induced RKO-ERM no. 28 cells
with siRNA no. 1 or no. 2 reduced (Po0.05) cell migration
(Figure 3B) when compared with the non-targeting siRNA. Second,
we determined whether the expression of a full-length CLCN4
cDNA would reiterate the effects on migration of the endogenously
trapped CLCN4 gene. Towards this end, an HA-tagged full-length
CLCN4 cDNA was subcloned into the pIRES-EGFP2 bicistronic
expression construct and stably transfected into RKO cells. Cells
were then selected with G418, and the GFP-positive pooled
population was analysed by western blotting using an anti-HA
antibody (Figure 4A). As expected, we detected the expression of
the full-length HA-tagged CLCN4 protein at the predicted size of
95kDa, but not non-HA-tagged CLCN4. More importantly, RKO
cells expressing full-length CLCN4 cDNA showed enhanced
migration (Po0.05) in two independent assays (Figure 4B,
Supplementary Data 2) and in vitro invasion (Figure 4C),
C
e
l
l
s
 
m
i
g
r
a
t
e
d
160
140
120
100
80
60
40
20
0
P<0.05
RKO-ERM no. 28 RKO tTA
R
K
O
-
E
R
M
 
n
o
.
 
2
8
Actin
CLCN4
R
K
O
 
t
T
A
Tetracycline present
Tetracycline absent
–+–+
Figure 2 Trapping of a gene stimulatory for cell migration. (A) The
indicated cells (5 10
4) grown for 72h with or without tetracycline
(2mgml
 1) were added to the upper chamber of transwell inserts. The
lower chamber contained 10% FBS. After 6h, cells migrating to the lower
surface of the membrane were stained, and the number of cells was
counted in five fields and averaged (±s.e.). Data are representative of at
least three experiments. (B) The indicated cells were treated with or
without 2mgml
 1 tetracycline for 72h, RNA was extracted and subjected
to RT–PCR (35 cycles) using primers specific for CLCN4 and actin.
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Figure 3 Knockdown of gene-trapped CLCN4 counters tumour cell
migration. RKO-ERM no. 28 cells, induced for CLCN4 expression by
tetracycline withdrawal, were transiently transfected with a CLCN4-
targeting (siRNA no. 1, 2, 3) or a non-targeting siRNA using lipofectamine
2000. After 48h, cells were either RNA extracted for semi-quantitation of
CLCN4 transcript levels by RT–PCR (35 cycles) using primers located in
exons 11 and 13 (A)o r5  10
4 cells were analysed for cell migration
(B) as per Figure 2. Data in B represent mean±s.e. values for triplicate
determinations. asterisk indicates, Po0.05 compared with that of the non-
targeting siRNA.
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Monolayer proliferation was unaffected by CLCN4 expression
(data not shown). Moreover, transient transfection of the CLCN4
siRNA no. 2 countered (Po0.05) this increased migration/
invasion, concomitant (Figure 4B, C) with silencing of the
exogenous construct (Figure 4D).
We then investigated whether knockdown of the CLCN4
transcript would interfere with cell migration and invasion.
Towards this end, we transduced LS174 colon cancer cells with
lentivirus particles bearing a CLCN4 shRNA or, as a control, a non-
targeting shRNA. After selection of a puromycin-resistant popula-
tion, the cells bearing CLCN4-targeting shRNA showed a 65–70%
reduction in transcript levels compared with their counterparts
expressing the non-targeting shRNA by quantitative PCR. We then
assayed these cells for their migratory capacity through a porous
filter. To remove investigator bias, images were digitised, stained
nuclei were ‘captured’ by Corel Photo-Paint (Corel, Ottawa,
Ontario, Canada) and quantified by ImageJ software (http://
rsb.info.nih.gov/ij/). In these assays, the LS174 cells bearing
CLCN4 shRNA were less migratory (Figure 5) compared with
control cells harbouring the non-targeting shRNA (13.8±1.7 vs
3.2±0.8%, filter area masked with nuclei), this difference being
statistically significant (P¼0.0002). We also compared the ability
of mouse fibroblasts wild type and null for CLCN4 for in vitro
invasiveness. Cells were seeded onto Matrigel-coated porous
filters, and after 22h, assayed for their ability to penetrate the
extracellular matrix-coated filter by staining cells on the lower
aspect of the membrane. We found that CLCN4 wild-type cells
showed about a twofold higher rate of invasion (area of filter
occupied with nuclei¼7.5±1.3 vs 3.9±0.8, P¼0.0159) compared
with their null counterparts (Figure 6). Thus, we conclude that the
wild-type CLCN4 does indeed contribute to cell migration.
To determine the generality of CLCN4 in augmenting cell
migration, a third colon cancer cell line (HCT 116) was stably
transfected with full-length CLCN4 and assayed for cell migration.
Similar to RKO colon cancer cells, CLCN4 overexpression (Figure 7B)
also yielded an enhanced migration (Po0.05) of HCT 116 cells
(Figure 7A). Thus, the modulatory effect of CLCN4 on tumour cell
migration is not restricted to RKO and LS174 colon cancer cell lines.
Elevated CLCN4 induces liver metastases
Owing to the fact that increased CLCN4 expression augmented in
vitro migration and invasion, we hypothesised that CLCN4 would
increase the metastatic ability of colon cancer cells. To answer this
question, RKO colon cancer cells overexpressing CLCN4, or the
vector alone, were injected into the spleen of nude mice. After
6 weeks, the livers were examined macroscopically for metastatic
nodules. Liver metastases was evident in 5 of 10 mice receiving
CLCN4-overexpressing RKO cells, whereas no metastatic nodules
were detected in vector controls. We verified continued over-
expression of CLCN4 in colon cancer metastases to the liver
(Figure 8A) by RT–PCR.
If CLCN4 promotes tumour spread, a high level of expression
would be predicted in liver metastases in colon cancer patients. We
therefore assayed CLCN4 transcript levels in a small series of
resected human primary tumours and liver metastases. We
observed a clear enrichment of CLCN4 expression in colon cancer
metastases to the liver for all nine patients over that evident with
primary tumours (Figure 8B). Although we cannot rule out the
possibility of a CLCN4 signal from the liver itself (Jentsch, 2008),
the tumour cellularity of the metastatic lesions was estimated to be
480%, making this possibility less likely. Nevertheless, to
eliminate investigator bias, we also queried the Gene Expression
Omnibus (GEO, http://www.ncbi.nlm.nih.gov/projects/geo/) expression
profiling database for CLCN4 overexpression in colon cancer
metastases. An elevated CLCN4 transcript level was again evident
in colon cancer metastases to the lymph nodes compared with
expression in the synchronous primary colon tumours (Figure 8C).
Note the absence of detection call for the GSM47872 primary
tumour sample. Taken together, these data suggest that CLCN4
stimulates colon cancer progression.
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Figure 4 Expression of a full-length CLCN4 induces colon cancer cell
migration. (A) A pool of RKO colon cancer cells stably expressing the
indicated constructs were lysed and 20mg protein was analysed by western
blotting using a rabbit anti-HA tag antibody (Invitrogen cat no. 715500),
followed by an HRP-coupled goat anti-rabbit IgG. Immunoreactive proteins
were visualised by enhanced chemiluminescence. Size markers are
indicated. (B) A pool of RKO clones overexpressing wild-type CLCN4
(RKO-CLCN4) or the empty vector (RKO (Vector)) were assayed for
migration as described in Figure 2 and using 10% FBS as chemoattractant.
(C) In vitro invasion was as described for the migration assays, with the
exception that a Matrigel-coated filter was used and cells traversing the
coated filter were enumerated 16h later. The experiment was repeated
three times and data are shown as average±s.e values. For (B) and (C), an
asterisk indicates Po0.05, in comparison with the RKO-CLCN4 data.
(D) RT–PCR was carried out for CLCN4 expression as described in
Figure 3.
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cytotoxicity
Considering the fact that CLCN4, as a proton/Cl exchanger,
extrudes protons from the cell against its electrochemical gradient
(Picollo and Pusch, 2005), we argued that cells overexpressing the
exchanger would be more resistant to the cytotoxic effect of an
extracellular proton load. To answer this question, we cultured
RKO cells overexpressing CLCN4, or the vector only, in an acidic
medium akin to the pH evident in the tumour microenvironment
(Gatenby and Gillies, 2004). Indeed, whereas over 35% of CLCN4-
overexpressing RKO cells survived the reduced pH of 6.6, only 10%
of vector controls tolerated the increased acidity (Figure 9), and
this difference was statistically significantly (P¼0.01).
DISCUSSION
Although there have been numerous investigations on genes
contributing to colon cancer development, few studies have been
undertaken to identify gene products implicated in colon cancer
invasion/migration/metastases. Moreover, most of these studies
have been empirical, focussing on ‘educated guesses’, with only a
few using agnostic genome-wide studies (Cajot et al, 1997;
Lombardi et al, 1999; Guan et al, 2000; Agrawal et al, 2002; Sordat
et al, 2002). We describe herein gene trapping of the Cl
 /H
þ
exchanger, CLCN4, as a novel promoter of colon cancer migration,
invasion and metastases. Further, we show that CLCN4 expression
is probably elevated in colon cancer metastases to the liver, our
findings being consistent with the observation of increased mRNA
levels in metastases to the lymph nodes as per a query of the GEO
database. As the region of the genome (Xp22.3) harbouring CLCN4
shows gain/amplification in 16% of colon cancer patients, we
presume that CLCN4 overexpression reflects, in part, increased
gene dosage.
Although, to our knowledge, this is the first report of a causal
role for CLCN4 in tumour progression, an earlier study (Soroceanu
et al, 1999) is relevant for showing that pharmacological blockade
of chloride channels was shown to reduce glioma cell migration
and invasion into foetal rat brain aggregates. Unfortunately, the
responsible chloride channel/exchanger driving migration/inva-
sion was not identified in that investigation and, at present, at least
11 separate chloride exchangers/antiporters have been reported
(Bustin et al, 2001; Jentsch, 2008). In contrast, the expression of
two other chloride channels (the Ca
2þ-dependent chloride
channels CLCA1 and CLCA2) was downregulated in 80% of
colorectal tumours, although the biological significance of this
repression (Bustin et al, 2001) remains to be determined. Other
ion transporters, in addition to the aforementioned chloride
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Figure 5 Knockdown of CLCN4 reduces migration of colon cancer cells. The indicated cells (100000) were seeded in triplicate in 10% FBS on porous
filters (8mm). The bottom well contained 20% FBS in McCoy’s 5A medium. After 6h, cells were scrubbed from the top aspect of the filter, cells on the
bottom aspect were fixed and stained with Hema-Diff, as instructed by the manufacturer. Images were taken using a Nikon Microphot-FXA microscope
(Nikon, Melville, NY, USA) at  100 magnification, digitised and the nuclear area was captured with Corel Photo-Paint (v.11) using the colour mask pick tool
feature to identify the nuclei. This image was captured and the nuclear area was quantified using ImageJ 1.42 software (http://rsb.info.nih.gov/ij/). Data are
shown as the average percentage area of the filter occupied with nuclei±s.d. values of at least four independent fields. Nuclei are marked with white arrows.
Statistical analysis was performed using an unpaired t-test and GraphPad Prism software version 5.02.
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migration/invasion. In this regard, silencing of MS4A12, a cell
surface protein that controls Ca
2þ flux into colon cells, attenuated
cell migration and invasion of malignant intestinal cells (Koslowski
et al, 2008). In addition, although implicated in tumour develop-
ment rather than cell invasion/metastases, SLC5A8, a sodium
symporter identified by a global search for genes that were
aberrantly methylated at high frequency in human colon cancer
and consequently repressed in expression (Li et al, 2003), was
characterised as a candidate tumour suppressor. Finally, and
reminiscent of our findings with CLCN4, expression of the ether a
go-go (Eag1) potassium channel is linked with tumour metastases,
in that its expression correlates with lymphatic node metastases
and organ metastases (Ding et al, 2007). However, whether Eag1 is
a driver of tumour spread or merely a passive bystander remains
to be determined.
As to the mechanism by which CLCN4 promotes colon cancer
migration, invasion and metastases, several possibilities can be
entertained. As CLCN4 is a known Cl
 /proton antiporter, the most
likely mechanism relates to its role in ion exchange (Jentsch, 2008).
Indeed, our unpublished findings that the general chloride channel
inhibitor attenuated the effects of CLCN4 overexpression on
tumour cell migration is in agreement with this contention,
notwithstanding the caveat that this blocker targets other chloride
channels as well. CLCN4 is displayed both at the cell surface and at
endosomal membranes, possibly cycling between both compart-
ments (Mohammad-Panah et al, 2002), and its ability to regulate
fluxes in both protons and chloride ions may have ramifications
both with respect to control of intracellular pH or the pH of
the endosomal compartment (Mohammad-Panah et al, 2002). As
discussed earlier, regulation of intracellular pH is critical
in tumour cells in which proton accumulation is high because of
incomplete glucose metabolism and a proton extrusion mechanism
is necessary to maintain a neutral or near neutral intracellular pH
(Gatenby and Gillies, 2004). In addition, regulation of pH in the
endosomal compartment (Mohammad-Panah et al, 2002) could
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Figure 6 Reduced invasiveness of null CLCN4 fibroblasts. These assays were as described for Figure 5, but with the following exceptions. The indicated
cells (20000) were seeded in triplicate on Matrigel-coated porous filters (8mm) and, after 22h, were assayed and quantified for invasion. Data are shown as
the average percentage area of the filter occupied with nuclei±s.d. values of at least four independent fields. Nuclei are marked with white arrows. Statistical
analysis was performed using a Mann–Whitney U-Test.
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invasiveness, in that the acidification of large intracellular
endosomal vesicles promotes proteolytic degradation of phagocy-
tosed extracellular matrix (Montcourrier et al, 1994). Indeed, the
quantitative presence of these vesicles correlates with cell
migratory capacity, at least in models of breast cancer
(Montcourrier et al, 1994). Alternatively, another possibility,
although not mutually exclusive, is that modulation of salt levels
as a consequence of chloride flux could yield water movement
into/out of cells, thereby altering the cell shape and/or size so as to
facilitate migration. In fact, such a mechanism was advanced to
explain the invasive phenotype of cultured glioma cells initiated by
volume-activated chloride fluxes (Ransom et al, 2001). Notwith-
standing these aforementioned potential mechanism(s), it is also
equally feasible that CLCN4 augments cancer progression through
a mechanism unrelated to its role as a chloride/proton exchanger.
Such an argument is not without precedent. Indeed, an in-frame
deletion that abrogated anion exchange of the DRA transporter
had no effect on the ability of the transporter to suppress
tumour growth (Chapman et al, 2002). Furthermore, the fact that
our endogenous CLCN4 gene trapped at exon 7, and therefore
devoid of a part of the transmembrane-spanning region, never-
theless promoted cell migration might point to an additional
mechanism(s).
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Figure 8 CLCN4 stimulates experimental metastases and is elevated in expression in metastases to the liver/lymph nodes. (A) Pooled RKO clones
overexpressing full-length CLCN4 cDNA (RKO-CLCN4) or the empty vector (RKO-vector) were injected (10
6 cells) into the spleen of groups of 10 nude
mice. After 6 weeks, the mice were killed and liver tissues were examined macroscopically for metastatic tumour nodules or subjected to RT–PCR for
CLCN4. (B) RNA extracted from a series of primary colon tumours and colon cancer metastases to the liver was subjected to RT–PCR for CLCN4
expression as per Figure 7. (C) Query of the Gene Expression Omnibus database (http://www.ncbi.nlm.nih.gov/projects/geo/) showing increased CLCN4
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Figure 9 CLCN4-overexpressing colon cancer cells are more resistant
to acid-induced cytotoxicity. Pooled RKO clones overexpressing full-length
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as a novel gene product that is stimulatory for colon cancer cell
migration, invasion and metastases. These findings, and others
(Soroceanu et al, 1999; Bustin et al, 2001; Chapman et al, 2002; Li
et al, 2003; Ding et al, 2007), should direct attention to the
importance of ion exchangers in tumour progression and could
provide new avenues for managing patients at high risk for
metastatic spread.
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